Ananda Developments PLC Presenting at Aquis Showcase

RNS Number : 6483K

Ananda Developments PLC

04 November 2024

 

4 November 2024

 

ANANDA DEVELOPMENTS PLC 

("Ananda" or the "Company") 

 

Presentation at Aquis Showcase

 

Ananda Developments plc (AQSE: ANA), a Company focused on the development of CBD based therapies for the treatment of a range of complex inflammatory pain conditions, is pleased to announce that it will be presenting at the Aquis Stock Exchange Showcase on Tuesday 12th November in London, at the Royal College of Surgeons, WC2A 3PE.

 

Finance Director Jeremy Sturgess-Smith will deliver an eight-minute pitch, followed by a rapid-fire Q&A session to a live investor audience.

 

The event will provide an  opportunity to hear directly from the management team on the Company's pharmaceutical product development plans and to connect with them in person.

 

Investors interested in attending can register here with the code 'AQ20'.

 

-Ends-

To stay abreast of the latest developments at Ananda, follow our social media channels at:  

  

·              Investor Hub: investors.anandadevelopments.com

·              Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=   

·              LinkedIn: https://www.linkedin.com/company/anadevelopments/   

·              Twitter: https://twitter.com/AnandaPlc

·              Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor

  

-Ends-  

  

The Directors of the Company accept responsibility for the contents of this announcement.  

  

ANANDA DEVELOPMENTS PLC	[phone]
	[e-mail]
Chief Executive Officer
Melissa Sturgess
Finance Director
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE LLP	[phone]
Corporate Finance
Richard Morrison
Corporate Broking
Abigail Wayne
Rob Rees
Yellow Jersey PR (media enquiries) Sarah MacLeod Charles Goodwin Zara McKinlay	[phone] [e-mail]

 

 

About Ananda Developments  

  

Ananda is an AQSE-listed life sciences company focused on the research and clinical development of CBD-based therapies for a range of complex inflammatory pain conditions.

For more information, please visit: https://anandadevelopments.com

   

https://investors.anandadevelopments.com/link/5PmQqP

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAGZMGMMMFGDZM